Skip to content

Speakers

Expand/Collapse

Stewart Abbot
SVP & CSO
Adicet Bio Inc.

Stewart Abbot is the chief scientific officer at Adicet Bio. He holds a B.Sc. in Biological Sciences (Edinburgh), M.Sc. in Biomedical Engineering (Glasgow) and Ph.D. in Pathology (London). His academic career focused on basic and translational science initiatives in vascular biology, pharmacology and toxicology. He joined Amersham Biosciences in 2000 and developed Amersham’s and, following acquisition, General Electric’s stem cell-based drug screening capabilities. He was head of the Molecular and Cellular Biology research laboratory at GE’s Global Research Center from 2004-2007. In 2007 he joined Celgene to develop novel cell-based therapeutic candidates and subsequently development of external cellular therapy R&D collaborations and alliances. In 2015 he joined Fate Therapeutics and held roles of VP translational research and chief development officer. He joined Adicet Bio. in June 2018 and his current role oversees all research associated with genetically engineered gamma delta T cell-based therapy development.

Day Two

Thursday 9TH May 2019

11:30 am | Development of Chimeric Antigen Receptor-Modified γδ T Cell Therapies for Solid and Liquid Tumors

Alison Moore
CTO
Allogene Therapeutics

Alison Moore, Ph.D., is the Chief Technical Officer for Allogene, overseeing product sciences, supply chain, manufacturing, quality and technical operations. Alison has extensive experience in all aspects of biomanufacturing and CMC product development, working in both operations and research and development. She most recently served as Senior Vice President, Process Development, at Amgen. Previously, she held senior roles at Amgen in Operations Technology, Process and Product Engineering, and Corporate Manufacturing. Prior to these positions, she was Vice President, Site Operations, at Amgen’s Fremont, Calif., manufacturing facility. Before joining Amgen, Alison was a Director in Chemistry, Manufacturing and Controls, Regulatory Affairs, at Genentech. She holds a Ph.D. in cell biology and a bachelor’s degree in pharmacology with honors from Manchester University, England. Following her doctoral degree work there, she was a postdoctoral research fellow at the Medical University of Lübeck, Germany, and at Genentech.

Day One

Wednesday 8TH May 2019

9:30 am | The Use of QTPP as a Tool in the Development of an Allogeneic Cell Therapy

Christopher Haqq
EVP, CSO
Atara Biotherapeutics

Dr. Christopher Haqq is EVP, Chief Scientific Officer at Atara Biotherapeutics. Previously he was Vice President for Clinical Research and Development at Cougar Biotechnology and Johnson & Johnson’s Janssen, where he was the lead clinician for a pivotal prostate cancer study leading to market approval for Zytiga® (abiraterone acetate). Chris has worked closely with the EMA and the U.S. FDA – filing IND applications, new drug applications, special protocol assessments and their international equivalents. Chris completed his M.D. and Ph.D. at Harvard Medical School and his B.S. at Stanford University. He is board certified in Medical Oncology and Internal Medicine.

Day Two

Thursday 9TH May 2019

4:30 pm | Pioneering an Off-the-Shelf, Allogeneic T-cell Platform for Epstein-Barr Virus (EBV)-Associated Cancers and MS

Greg Liposky
SVP, Commercial Manufacturing
Athersys

Mr. Liposky joined Athersys in 2018 as Senior Vice President of Commercial Manufacturing. In his role, Mr. Liposky is responsible for providing oversight for clinical manufacturing of MultiStem® cell therapy and establishing the long-term strategic plan for commercial manufacturing of the product. Mr. Liposky has over 35 years of experience in biotherapeutic protein process development and manufacturing on both a clinical and commercial level. Prior to joining Athersys, Mr. Liposky served as Vice President of Technical Operations for Mallinckrodt Pharmaceuticals where he led technical support of its Autoimmune and Rare Disease product portfolio. Before joining Mallinckrodt, Mr. Liposky served as Vice President of Contract Manufacturing for Questcor Pharmaceuticals where he managed the supply chain for Questcor’s lead product, H.P. Acthar® Gel. Before his tenure at Questcor, Mr. Liposky was Vice President and General Manager for MedImmune, a division of AstraZeneca. In this position, Mr. Liposky was responsible for the management of MedImmune’s large-scale mammalian cell culture manufacturing facility supporting clinical manufacturing of MedImmune’s pipeline product, as well as the commercial supply of AstraZeneca’s key therapeutic monoclonal antibodies, Synagis®. Prior to that role, Mr. Liposky was responsible for the commissioning, validation and licensure of MedImmune’s large-scale mammalian cell culture manufacturing plant. Mr. Liposky also served as Senior Vice President of Operations for GTC BioTherapeutics where he led all Operations and Quality functions for the organization and was responsible for overseeing the Business Development function as a senior member of the management team involved in various product development partnerships. Further, Mr. Liposky has held positions of increasing responsibility at Creative BioMolecules, Verax Corporation and Worthington Biochemical.

Day Two

Thursday 9TH May 2019

10:00 am | Establishing Long-Term Strategic Plans for Commercial Manufacturing of Allogeneic Cell Therapies

5:00 pm | Chair’s Closing Remarks

1:30 pm | Panel Discussion: Allogeneic Innovation and Collaboration

8:45 am | Chair’s Opening Remarks

David Sourdive
EVP - Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.

Day One

Wednesday 8TH May 2019

12:30 pm | Transforming Adoptive T-cell Therapy with Gene-editing

Andre Choulika
Chairman & CEO
Cellectis

André Choulika, Ph.D., is one of the founders of Cellectis and served as Chief Executive Officer since the company's inception in 1999. He is Chairman of the Board of Directors since 2011 and President of Calyxt since August 2010. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies  and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from the HEC (Challenge +).

Day One

Wednesday 8TH May 2019

8:30 am | Allogeneic Cell Therapies as the Future of CAR-T

Ross Durland
SVP, Development
Cell Medica

Ross has over 25 years of experience in the development of innovative therapeutic products and technologies and is responsible for spearheading the product development process at Cell Medica. His experience includes eight years developing human gene therapies at Valentis, where he became Senior Director Preclinical Development. In this role, he led multisite, multidisciplinary product development teams, advancing two new gene therapy products from animal proof-of-concept to human clinical testing, and supported development of five additional clinical stage products through Phase IIb testing. He was also responsible for Valentis’ manufacturing and quality control functions in manufacturing products for preclinical and clinical testing. Ross also served as Vice President of Product Development at Altea Therapeutics, where he led preclinical and clinical development of two novel human transdermal therapeutic products. Ross has a PhD in molecular biology from the University of California San Diego and a BS in biology from Texas A&M University.

Day Two

Thursday 9TH May 2019

9:30 am | Allogeneic Natural Killer T (NKT) Cells for CAR-Mediated Cancer Therapy

Xiaokui Zhang
CSO
Celularity

Dr. Xiaokui Zhang has 15+ years of experience in leading discovery, research and development in the biopharmaceutical industry to advance research stage programs into early clinical development. She joined Celularity in August 2017 as EVP, Chief Scientific Offer to head Research & Development operations in immuno-oncology and functional regeneration. Her previous roles included Senior Director of Research at Celgene Cellular Therapeutics where she led the development of novel immunotherapy candidates derived from placental progenitor cells and initiated clinical trials. She holds a B.Sc. in Physiology from Nanjing University, Ph.D. in Molecular Cell Biology from the Rockefeller University with further post-doctoral training in the Functional Genomics Department of Novartis Pharmaceuticals.

Day One

Wednesday 8TH May 2019

11:00 am | An Allogeneic, Off-the-Shelf NK Cell Product Derived from Placental Hematopoietic

Jean-Pierre Latere
COO
Celyad

Jean-Pierre joined Celyad in January 2016 and is responsible for strengthening the organization and key processes in manufacturing, quality, program management, clinical operations and regulatory affairs. He started his career as a Research Associate at the Michigan State University in the US. Following that assignment, he moved to the Johnson & Johnson group where he held various positions, from Scientist to Senior Scientist. He then joined Cardio3 BioSciences in 2008 as Project Manager Delivery System and left the company in 2012 in the position of Senior Director Business Development. Prior to joining Celyad, Jean-Pierre served as Beauty Care and Healthcare Market Global Leader at Dow Corning. Jean-Pierre holds a PhD in Chemistry from the University of Liège, Belgium.

Day One

Wednesday 8TH May 2019

2:30 pm | Perspectives on Developing Non-gene Edited Allogeneic CAR T Therapies

Jon Terrett
Head of Immuno-Oncology Research and Translation
CRISPR Therapeutics

Dr. Jon Terrett has an extensive track record of discovering and progressing immuno-oncology drug candidates into the clinic. Prior to joining our company, Jon served as the Vice President of Oncology Discovery for CytomX, an oncology-focused biotechnology company focused on developing a novel class of antibody therapeutics. In addition, Jon has held various R&D leadership roles in biopharma, including serving as the Chief Scientific Officer at Oxford Biotherapeutics, and as a director at various biotechnology companies including Medarex, CellTech and Oxford Glycosciences. Jon received a Ph.D. in genetics at the University of Nottingham and a B.S. in genetics at the University of Sheffield.

Day One

Wednesday 8TH May 2019

12:00 pm | CRISPR/Cas9 Enables the Efficient Production of Allogeneic CAR-T Cells Engineered to Contain Multiple Genome Edits to Enhance Therapeutic T-Cell Function

Robert Igarashi
CSO
CytoSen Therapeutics

Robert Igarashi, Ph.D. is the president and co-founder of CytoSen Therapeutics. Dr. Igarashi has a diverse background in life sciences and has played an instrumental role in the development of the particle based natural killer (NK) cell stimulating technology. He has brought his biochemical and physico-chemical expertise to combine with immunology for developing and refining the nanoparticle based method for NK cell stimulation that could be used for ex vivo expansion as well as in vivo stimulation of therapeutic NK cells.He has been crucial in understanding the biochemical aspects of the plasma membrane particles interacting with NK cells and how they can be further innovated to add novel therapeutic dimensions for adoptive NK cell therapy.

Workshop A

May 7, 2019

9:00 am | Effective Scale-Up to Achieve Commercialization of Allogeneic Cell Therapies

Day One

Wednesday 8TH May 2019

2:00 pm | Incorporation of Semi-Automated Methods for Manufacture of High Dose NK Cells Using the PM21 Platform

Bob Valamehr
CDO
Fate Therapeutics

Bob Valamehr is the Chief Development Officer at Fate Therapeutics, overseeing the company’s early development activities including “off-the-shelf” cell therapy products derived from the company’s induced pluripotent stem cell platform. Previously, Dr. Valamehr was the Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.

Day One

Wednesday 8TH May 2019

5:35 pm | End of Day One

5:30 pm | Chair’s Closing Remarks

9:00 am | Pluripotent Stem Cell Product Platform as a Unique Means to Mass Produce Off-the-Shelf Allogeneic Cell Products

8:15 am | Chair’s Opening Remarks

Harpreet Singh
President & CEO
Immatics

Harpreet Singh co-founded Immatics in 2000. Since then he has served as Managing Director and Chief Scientific Officer of Immatics Biotechnologies GmbH, helping to grow the company from a start-up to an established biotech and playing a leading role in raising over US$350m of funding through private equity, grants and licensing agreements. He is dedicated to translating pioneering scientific discoveries into highly innovative cancer immunotherapies with clinical utility. Since 2015, Harpreet Singh is President & CEO of Immatics US, Inc. overseeing all operations of Immatics in Houston, Texas as to develop next-generation Adoptive Cell Therapies (ACT).

Day One

Wednesday 8TH May 2019

3:00 pm | Novel Allogeneic Cell Therapies for Treatment of Solid Cancers

Yannick Bulliard
Director, Off-the-Shelf Therapies
Immatics

In 2016, Yannick Bulliard joined Immatics US, Inc. as Director Product Science, where he established the Department’s core activities in process development, development of immunoassays and quality control. Since 2017, Dr. Bulliard is leading the translational development of ACTallo®, Immatics’ allogeneic cellular therapy platform based on γδ T cells. Prior to Immatics, Dr. Bulliard was a project lead for several preclinical assets in Immuno-Oncology at Amgen, CA. He obtained his Ph.D. from the EPFL, Switzerland and went on to pursue a postdoctoral fellowship at Novartis in Cambridge, MA.

Day Two

Thursday 9TH May 2019

11:00 am | ACTallo®: Off-the-Shelf γδ T Cell Therapy Engineered Against Novel Tumor Targets

Michael Har-Noy
Founder, CEO & CSO
Immunovative Therapies

Dr. Har-Noy is the founder and inventor of the Mirror Effect technology and serves as the CEO and Chief Science Officer of the parent Immunovative Therapies, Ltd., as well as the President of Immunovative Clinical Research, Inc, the wholly-owned Clinical Research Organization of Immunovative located to Phoenix, AZ USA. Dr. Har-Noy also serves as a consultant to the Center of Excellence for Cancer Treatment and Immunotherapy Research at the Department of Bone Marrow Transplantation and Cancer Immunotherapy at Hadassah-Hebrew University Medical Center in Jerusalem.  Early in his career, he received the National Beta Beta Beta research society first place award for undergraduate research for developing a bioreactor device which was able to maintain rat ovaries alive and cycling outside the body. As a MD-PhD student at Rush University Medical School/Loyola University he developed the first commercial scale hollow-fiver bioreactor for the production of monoclonal antibodies and other mammalian cell-derived products.  Dr. Har-Noy previously developed an autologous Th1 cell therapy for advanced cancer. While a Research Fellow at Harvard Medical School, Department of Immunology, he developed a CD4 viral-purged autologous therapy for HIV.  Dr. Har-Noy brings over 30 years’ experience in translational research in immunology and bioengineering, including pre-clinical development, manufacturing and clinical trials/regulatory affairs.

Day Two

Thursday 9TH May 2019

3:00 pm | Next Generation Immunotherapy

Lawrence Lamb
CSO
Incysus

Dr. Lamb was first to describe the association between relapse-free survival and gdT cell recovery in bone marrow transplant patients. For 26 years, most recently as Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham, Dr. Lamb developed the scientific support for gdT cell-based immunotherapies. Today, this work has brought us to the first clinical trials for allogeneic gdT cell therapy in leukemia patients undergoing haploidentical stem cell transplants and the first gene-modified gdT cell therapy for glioblastoma. Dr. Lamb currently directs clinical and translational research strategy and operations for Incysus Therapeutics.

Day Two

Thursday 9TH May 2019

9:00 am | Driving the Road to Off-the-Shelf Allogeneic γδT Cell Therapies

Minh Hong
Head of Allogeneic Cell Therapy Commercial Development
Lonza

Dr. Minh Hong is the global commercial development director for Lonza’s allogeneic cell therapy business, which includes manufacturing sites in the US, Europe, and Asia. Prior to this, he worked as a strategic account and business development manager for some of Lonza’s top cell and gene therapy clients. Dr. Hong holds a Ph.D. degree from the University of Minnesota, and completed postdoctoral studies at the University of Minnesota and Harvard University.  

Day Two

Thursday 9TH May 2019

1:30 pm | Panel Discussion: Allogeneic Innovation and Collaboration

Hans Klingemann
VP, Research & Development
NantKwest

Dr. Klingemann has served as the company’s Vice President of Research & Development since joining full time in 2012. He is also the discoverer of the NK-92 cell line and co-founder of the company. Dr. Klingemann received his M.D. from the University of Würzburg Medical School, and his Ph.D. from the University of Marburg, Germany. Prior to joining NantKwest, Dr. Klingemann served as the Director of the Bone Marrow and Stem Cell Transplant Program and the Director for Hematological Malignancies at Tufts Medical Center in Boston. Dr. Klingemann also served as Director of the Section of Bone Marrow Transplant & Cell Therapy at Rush University Medical Center in Chicago where he established the first clinical GMP Cell Therapy facility in the Chicago area. Over the past 25 years, Dr. Klingemann has conducted National Cancer Institute supported research on how to engineer the patient’s immune system to fight cancer. He maintains an academic appointment at Tufts University Medical School.

Day Two

Thursday 9TH May 2019

12:30 pm | NantKwest's Approach to Commercializing Allogeneic Cell Therapies

Ralph Bradenberger
VP, Development & Manufacturing
Nkarta Therapeutics

Ralph Brandenberger is the Vice President, Development and Manufacturing of Nkarta. Ralph has broad experience in process development, technical operations and manufacturing of cellular therapeutics and biologics. Most recently, as Sr. Director of Process Development at Neurona Therapeutics, Ralph created the manufacturing strategy for Neurona’s novel cell therapy platform. Prior to that, Ralph was Head of Technical Operations with oversight of Manufacturing Sciences, Analytical Sciences and GMP Cell Banking at Baxalta Hayward, a GMP manufacturing plant of both clinical stage biologics and reagents used in commercial drug substance manufacturing. Ralph was previously the Director of Process Sciences for Cellular Therapeutics at Geron Corporation. There he was responsible for process development from nonclinical research through early clinical cGMP manufacture, and technology development for commercial manufacturing. Dr. Brandenberger received a MS and PhD in Cell Biology from the Biocenter of the University of Basel, Switzerland. He did his postdoctoral training at the Howard Hughes Medical Institute at the University of California, San Francisco.

Day One

Wednesday 8TH May 2019

11:30 am | Development of a Scalable Manufacturing Platform for Off-the-Shelf Genetically Engineered, Allogeneic Natural Killer (NK) Cell Products

Shaun Stapleton
Head of Regulatory Affairs
ReNeuron

Shaun Stapleton was appointed Head of Regulatory Affairs in June 2015. He joined ReNeuron from RRG (a Voisin Consulting Life Sciences Company) where he was a Director and Vice President of Regulatory Science. He supported clients on a number of global development and registration projects, including advanced therapies and orphan drugs. Having graduated in Biochemistry from Imperial College, London, he began his career in research with the Imperial Cancer Research Fund, before moving into the pharmaceutical industry. He held positions of increasing responsibility in regulatory affairs at Sterling Winthrop, Eli Lilly and Boehringer Ingelheim before becoming Senior Director of Regulatory Affairs at Ipsen, where he managed regulatory input into development programmes globally, securing new product approvals in the US, EU and internationally in the neurology, endocrinology and oncology therapeutic areas.

Day One

Wednesday 8TH May 2019

3:30 pm | Regulatory Challenges and Opportunities for Allogeneic Cell Therapies: Theory and Real World Experiences

Sophie Amsellem- Bosq
CAR-T Program Director
Servier

Sophie Amsellem-Bosq joined Servier end 2017 as CAR-T Program Director. She is responsible for the strategy and the cross functional management of the CAR-T portfolio. Prior to this, she held the position as Head of Genetically Modified Cells Therapy Unit at Yposkesi/Genethon CDMO (2014) as well as various positions at Institut Gustave Roussy (2005) (Biotherapy Clinical Investigation Center) as a board certified specialist in hematology biology. Sophie serves as a junior attending in immuno-hematology biology at Hôpitaux de Paris following her fellowship. She was a researcher in hematopoiesis at Institut National de la Recherche Médicale (INSERM), Institut Cochin and support, in 2002, her doctorate in “Blood cells biology”.

Day Two

Thursday 9TH May 2019

4:00 pm | Allogeneic CAR-Ts: Effective Therapies to Cure Cancer?

1:30 pm | Panel Discussion: Allogeneic Innovation and Collaboration

Angela Scott
COO
TCBiopharm

Angela has 32 years in oncology research and regenerative medicine, was part of the team that cloned ‘Dolly the Sheep’, and has designed, built and commissioned several GMP manufacturing facilities. She manufactured product for the UK’s ‘first-in-man’ stem cell trial (PISCES – ReNeuron), and has held MHRA -MIA and -IMP licenses for several cell therapy products.

Workshop B

May 7, 2019

1:00 pm | Building Your Own GMP Infrastructure for CAR-T - Commercial, Clinical and Regulatory Considerations

Michael Leek
CEO
TCBiopharm

Recently presented the 'Scottish Life-Sciences Entrepreneurial Business Leadership' award, Michael is CEO of TC BioPharm, developing clinical-stage allogeneic CAR-T immunotherapies. Active in the cell therapy sector for 30 years, Michael has developed ten different cell-based products to clinic including the world’s first allogeneic cell therapy to undergo multi-national (EU, US, Canada) phase 3 evaluation when he was previously responsible for moving Intercytex from a pre-clinical startup, to an AIM-listed company.

Workshop B

May 7, 2019

1:00 pm | Building Your Own GMP Infrastructure for CAR-T - Commercial, Clinical and Regulatory Considerations

Day Two

Thursday 9TH May 2019

12:00 pm | Step-wise Clinical Development of Allogeneic γδ CAR-T Based Products